Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation

Cancer Research

Volumn 66, Issue 18, 2006, Pages 8966-8970

  Sodha, Nayanta ^a   Mantoni, Tine S ^b   Tavtigian, Sean V ^c   Eeles, Rosalind ^d   Garrett, Michelle D ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b Cancer Research UK Centre for Cancer Therapeutics   (France)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; ETOPOSIDE;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CHEMICAL ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; GENE MUTATION; GERM LINE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DNA DAMAGE; ENZYME ACTIVATION; ETOPOSIDE; GERM-LINE MUTATION; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROTEIN ISOFORMS; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE ALIGNMENT; TRANSFECTION;

EID: 33749497506     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1990     Document Type: Article

References (21)

1. Bartek J, Lukas J. Chk1 and chk2 kinases in checkpoint control and cancer. Cancer Cell 2003;3:421-9.
2. Ahn J, Urist M, Prives C. The Chk2 protein kinase. DNA Repair (Amst) 2004;3:1039-47.
3. Ahn JH, Li X, Davis HL, Canman CE. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J Biol Chem 2002;277:19389-95.
4. Lee CH, Chung JH. The hCds1 (CHK2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem 2001;4:30537-41.
5. Wu X, Webster SR, Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 2001;276:2971-4.
6. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
7. Cybulski C, Gorski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
8. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
9. Sodha N, Bullock S, Taylor R, et al. CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild-type allele in tumours. Br J Cancer 2002;87:1445-8.
10. Dufault MR, Betz B, Wappenschmidt B. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 2004;110:320-5.
11. Sodha N, Houlston RS, Bullock S, et al. Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 2002;20:460-2.
12. Poirot O, Suhre K, Abergel C, O'Toole E, Notredame C. 3DCoffee@igs: a web server for combining sequences and structures into a multiple sequence alignment. Nucleic Acids Res 2004;32:37-40.
13. Li J, Williams BL, Haire LF, et al. Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell 2002;9:1045-54.
14. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4.
15. Tavtigian SV, Deffenbaugh AM, Yin L, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with reclassification of eight substitutions as neutral. J Med Genet 2006;43:295-305.
16. Lee SB, Kim SH, Bell DW, et al. Destabililization of chk2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 2001;61:8062-7.
17. Bode AM, Dong Z. Post translational modification of p53 in tumorigenesis. Nat Rev cancer 2004;4:793-805.
18. Oldenburg RA, Kroeze-Jansema K, Kraan J, et al. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7.
19. van Puijenbroek M, van Asperen CJ, van Mil A, et al. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectral cancer does not lead to a severe clinical phenotype. J Pathol 2005;206:198-204.
20. Takai HK, Naka KY, Okada Y, et al. Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 2002;21:5195-205.
21. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004;1654:105-22.